Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia

NCT04040621 | Terminated Phase 1 Results FDA Drug

• 3 other identifiers: C35910252018-002841-12EMBA
• Study Type: interventional
• Target: 4
• Locations: 2 countries
• Sites: 4

Brief Summary

This is a multicenter, multinational, open label single dose pharmacokinetic (PK) study enrolling at least 32 subjects. The study aims to characterize the pharmacokinetics (PK) of a single intravenous dose of CAZ AVI in pediatric subjects aged 3 months to less than 18 years who are receiving systemic antibiotic therapy for suspected or confirmed nosocomial pneumonia, including ventilator associated pneumonia.

Conditions

Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia

Keywords

nosocomial pneumonia, NP

Outcome Measures

Primary Outcomes (11)

• Plasma Concentration Time Summary for Ceftazidime and Avibactam

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

• Area Under the Plasma Concentration-Time Profile From Time 0 to 8 Hours (AUC0-8 Hours)

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8 hours post dose

• Area Under the Curve From Time Zero to Extrapolated Infinite Time of CAZ-AVI (AUCinf)

  AUCinf = AUClast + (Clast\*/ kel), where Clast\* is the estimated concentration at the time of the last quantifiable concentration and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

• Area Under the Concentration-Time Profile From Time 0 to Time to Last Quantifiable Concentration (AUClast) of CAZ-AVI

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

• Maximum Observed Plasma Concentration (Cmax) of CAZ-AVI

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

• Time to Last Quantifiable Plasma Concentration (Tlast) of CAZ-AVI

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

• Time to Reach Maximum Observed Plasma Concentration (Tmax) of CAZ-AVI

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

• Termination Elimination Half-Life (t1/2) of CAZ-AVI

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

• Clearance (CL) of CAZ-AVI

  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose (apparent clearance) is influenced by the fraction of the dose absorbed. CL = Dose/AUCinf.

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

• Volume of Distribution of CAZ-AVI

  Volume of distribution at steady state (Vss) = Clearance (CL) × Mean Residence Time (MRT), MRT = Area under the first moment curve from 0 time to infinity (AUMCinf)/AUCinf - (infusion time/2), AUMCinf = AUMClast + (t × Cest1\*/kel) +(Cest1\*/kel2), 1Cest = e(-KEL × Tlast) × KELC0 , where C0 is the back-extrapolated concentration at time zero.

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

• Volume of Distribution During Terminal Phase (Vz) of CAZ-AVI

  Vz = Dose/(AUCinf × kel).

  Day 1: 2, 2.25, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 13, 24 hours post dose

Secondary Outcomes (4)

• Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

  Day 1 up to maximum of 35 days after last dose of study treatment (maximum of 36 days)

• Number of Participants With Death and Discontinuations Due to Adverse Events (AEs)

  Day 1 up to maximum of 35 days after last dose of study treatment (maximum of 36 days)

• Number of Participants With Clinically Significant Abnormal Laboratory Values

  Baseline up to Day 3

• Number of Participants With Clinically Significant Physical Examination Abnormalities

  Baseline up to Day 3

Study Arms (1)

Ceftazidime-avibactam

EXPERIMENTAL

This arm includes 4 cohorts

Drug: Ceftazidime-avibactam

Interventions

Ceftazidime-avibactam DRUG

Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.

Ceftazidime-avibactam

Eligibility Criteria

• Age: 3 Months - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Evidence of a personally signed and dated informed consent document indicating that the subject's parent(s), legal guardian, or legally acceptable representative has been informed of all pertinent aspects of the study. As appropriate per local requirements informed assent of subjects must also be documented.
• Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
• Male or female children age ≥3 months to \<18 years at Screening:
• Cohort 1: age 12 years to \<18 years;
• Cohort 2: age 6 years to \<12 years;
• Cohort 3: age 2 years to \<6 years;
• Cohort 4: age 3 months to \<2 years (must be born ≥37 weeks gestational age).
• Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected or confirmed HAP or VAP meeting the following criteria, and expected to require hospitalization until after the follow up evaluations are completed on Day 3 (48 hours after the end of infusion):
• Onset of symptoms ≥48 hours after admission or \<7 days after discharge from an inpatient acute or chronic care facility;
• New or worsening infiltrate on chest X ray;
• At least 1 of the following systemic signs prior to the initiation of treatment for Nosocomial Pneumonia:
• i. Fever (temperature \>38°C) or hypothermia (rectal/core temperature \<35°C); ii. White blood cell (WBC) count \>10,000 cells/mm3, or WBC count \<4,500 cells/mm3, or \>15% band forms.
• d. At least 2 of the following respiratory signs or symptoms: i. A new onset of cough (or worsening of cough). ii. Production of purulent sputum or endotracheal secretions. iii. Auscultatory findings consistent with pneumonia/pulmonary consolidation (eg, rales, rhonchi, bronchial breath sounds, dullness to percussion, egophony).
• iv. Dyspnea, tachypnea or hypoxemia (O2 saturation \<90% or PaO2 \<60 mmHg while breathing room air).
• v. A need for mechanical ventilation or, for already ventilated subjects, acute changes made in the ventilator support system to enhance oxygenation, as determined by, for example arterial blood gas or worsening PaO2/FiO2.

You may not qualify if:

• Subjects with any of the following characteristics/conditions will not be included in the study:
• Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
• Participation in other studies involving investigational drug(s) within 30 days prior to study entry and/or during study participation.
• Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
• Past or current history of epilepsy or seizure disorder (excluding childhood febrile seizures.
• Severe renal impairment defined as creatinine clearance (CrCL) ≤30 mL/min/1.73 m2 calculated using the child's measured height (length) and serum creatinine with the Bedside Schwartz equation (Schwartz, Munoz, et al., 2009):3 CrCL (mL/min/1.73 m2) =
• Documented history of any hypersensitivity or allergic reaction to any β lactam antibiotic.
• Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of CAZ AVI.
• Acute hepatitis in the prior 6 months, a prior history of cirrhosis, acute hepatic failure, or acute decompensation of chronic hepatic failure; and/or any of the following blood test results, for any individual, when assessed for eligibility:
• Bilirubin \>3 × upper limit of normal (ULN), unless isolated hyperbilirubinemia is directly related to the acute infection or due to known Gilbert's disease;
• ALT or AST \>3 × ULN values used by the laboratory performing the test. Subjects with values \>3 × ULN and \<5 × ULN are eligible if this value is acute and directly related to the infectious process being treated. This must be documented;
• ALP \>3 × ULN. Subjects with values \>3 × ULN and \<5 × ULN are eligible if this value is acute and directly related to the infectious process being treated. This must be documented.
• Any condition (eg, septic shock, burns, cystic fibrosis, acute hemodynamic instability, including those conditions not responding to pressor support) that would make the patient, in the opinion of the Investigator, unsuitable for the study (eg, would place a patient at risk; compromise the quality of the data; or interfere with the absorption, distribution, metabolism, or excretion of CAZ AVI).
• Receipt of a blood or blood component or scheduled for transfusion within the PK sampling period (eg, red blood cells, fresh frozen plasma, platelets) transfusion during the 24 hour period before enrollment.
• Body mass index (BMI) below the 5th percentile or above the 95th percentile for height, age, and weight except for children \<2 years of age as BMI is not considered a screening tool for healthy weight in children under 2 years of age.

Sponsors & Collaborators

• Pfizer: lead
• AbbVie: collaborator

Study Sites (4)

Wuxi Children's Hospital

Wuxi, Jiangsu, 214023, China

Location

Chengdu Women's and Children's Central Hospital

Chengdu, Sichuan, 610091, China

Location

Taipei Municipal Wanfang Hospital

Taipei, 116, Taiwan

Location

Chang Gung Memorial Hospital-Linkou

Taoyuan, 333, Taiwan

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Healthcare-Associated Pneumonia

Interventions

avibactam, ceftazidime drug combination

Condition Hierarchy (Ancestors)

Cross Infection; Infections; Pneumonia; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases; Iatrogenic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Limitations and Caveats

Only 4 participants were enrolled in this study. Outcome measures and AE data were not reported by cohort as planned in the protocol because doing so would risk re-dentification of the individual participants.

Results Point of Contact

• Title: Pfizer ClinicalTrials.gov Call Center
• Organization: Pfizer Inc.

ClinicalTrials.gov_Inquiries@pfizer.com

18007181021

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Non-randomized, single arm

Study Record Dates

• First Submitted: July 26, 2019
• First Posted: August 1, 2019
• Study Start: June 15, 2020
• Primary Completion: April 9, 2021
• Study Completion: May 7, 2021
• Last Updated: September 9, 2022
• Results First Posted: September 9, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

TW (2); CN (2)